TriangleNCT00509041 · OUTCOME
Progression Free Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- weeks
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Time from registration to progression or death (up to 3 years)
What was measured
Progression free survival (PFS) was defined as the time from registration to progression or death of any cause. Progression free and alive patients were censored at the date of last follow-up. The median PFS with 95% CI was estimated using the Kaplan Meier method.
Groups in this outcome
Dasatinib
Use of dasatinib (50 mg orally twice a day) in treatment of pts with previously treated malignant mesothelioma
| Group | Source count |
|---|---|
| Dasatinib | 43 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Dasatinib | 9.1 | Not reported | 7.4 | 16.9 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 7.4
- upper Limit
- 16.9
- value
- 9.1
- denoms
- counts
- group Id
- OG000
- value
- 43
- units
- Participants
- description
- Progression free survival (PFS) was defined as the time from registration to progression or death of any cause. Progression free and alive patients were censored at the date of last follow-up. The median PFS with 95% CI was estimated using the Kaplan Meier method.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Use of dasatinib (50 mg orally twice a day) in treatment of pts with previously treated malignant mesothelioma
- id
- OG000
- title
- Dasatinib
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- Time from registration to progression or death (up to 3 years)
- title
- Progression Free Survival
- type
- SECONDARY
- unit Of Measure
- weeks
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice